Partial cystectomy for muscle-invasive bladder cancer offers metastasis- and cancer-free survival comparable to that of radical cystectomy, but with less perioperative morbidity. Partial and radical ...

First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for ...

The US Food and Drug Administration (FDA) has granted approval to Inlexzo (gemcitabine intravesical system) for the treatment of certain types of bladder cancer. This decision marks a milestone for ...

Radical cystectomy involves bladder removal and urinary diversion, often using a laparoscopic robot-assisted approach for precision and access. The surgery lasts four to six hours, with a recovery ...

After decades of limited options, a groundbreaking FDA-approved treatment is opening new doors for people with certain types of bladder cancer. Supported by Johnson & Johnson Bill is a real patient ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

Bladder cancer affects many people every year, and despite that, false and outdated beliefs of the people still prevail. While some mistakenly think bladder cancer affects only the older population, ...

Bladder cancer develops when abnormal cells grow uncontrollably in the tissue layers of the bladder. While often thought of as a single condition, bladder cancer exists in multiple forms, each with ...